Global metabolic consequences of the chromogranin A-null model of hypertension: Transcriptomic detection, pathway identification, and experimental verification

Physiological Genomics

Volumn 40, Issue 3, 2010, Pages 195-207

  Friese, Ryan S ^a,b   Gayen, Jiaur R ^b,d   Mahapatra, Nitish R ^e   Schmid Schönbein, Geert W ^a   O'Connor, Daniel T ^b,c,d   Mahata, Sushil K ^b,d  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c University of California San Diego   (United States)

^d VA SAN DIEGO HEALTHCARE SYSTEM   (United States)

^e INDIAN INSTITUTE OF TECHNOLOGY MADRAS   (India)

Author keywords

Cholesterol; Essential hypertension; Gene expression; Insulin resistance; Metabolic syndrome; Microarray; Transcriptome

Indexed keywords

CHOLESTEROL; CHROMOGRANIN A; GLUCOSE; INSULIN; PANCREASTATIN; TRANSCRIPTOME; TRIACYLGLYCEROL;

ADRENAL GLAND; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CHOLESTEROL SYNTHESIS; CONTROLLED STUDY; ESSENTIAL HYPERTENSION; GENE EXPRESSION; GENETIC VARIABILITY; GLUCOSE BLOOD LEVEL; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; INSULIN SENSITIVITY; KNOCKOUT MOUSE; LIVER; METABOLIC SYNDROME X; MICROARRAY ANALYSIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; SECRETORY GRANULE; TRANSCRIPTION REGULATION; WILD TYPE;

ANIMALS; BLOOD GLUCOSE; CHROMOGRANIN A; GENE EXPRESSION PROFILING; HYPERTENSION; METABOLIC SYNDROME X; MICE; MICE, KNOCKOUT; MICE, TRANSGENIC; MODELS, ANIMAL;

EID: 76549133916     PISSN: 10948341     EISSN: 15312267     Source Type: Journal    
DOI: 10.1152/physiolgenomics.00164.2009     Document Type: Article

References (30)

1. Cadman PE, Rao F, Mahata SK, O'Connor DT. Studies of the dysglycemic peptide, pancreastatin, using a human forearm model. Ann NY Acad Sci 971: 528-529, 2002.
2. Chen Y, Rao F, Rodriguez-Flores JL, Mahapatra NR, Mahata M, Wen G, Salem RM, Shih PA, Das M, Schork NJ, Ziegler MG, Hamilton BA, Mahata SK, O'Connor DT. Common genetic variants in the chromogranin A promoter alter autonomic activity and blood pressure. Kidney Int 74: 115-125, 2008.
3. Chen Y, Rao F, Rodriguez-Flores JL, Mahata M, Fung MM, Stridsberg M, Vaingankar SM, Wen G, Salem RM, Das M, Cockburn MG, Schork NJ, Ziegler MG, Hamilton BA, Mahata SK, Taupenot L, O'Connor DT. Naturally occurring human genetic variation in the 3′-untranslated region of the secretory protein chromogranin A is associated with autonomic blood pressure regulation and hypertension in a sexdependent fashion. J Am Coll Cardiol 52: 1468-1481, 2008.
4. Dennis G, Jr, Sherman BT, Hosack DA, Yang J, Gao W, Lane HC, Lempicki RA. DAVID: Database for Annotation, Visualization, and Integrated Discovery. Genome Biol 4: P3, 2003.
5. Friese RS, Mahboubi P, Mahapatra NR, Mahata SK, Schork NJ, Schmid-Schoenbein GW, O'Connor DT. Neuroendocrine transcriptome in genetic hypertension: multiple changes in diverse adrenal physiological systems. Hypertension 43: 1301-1311, 2004.
6. Friese RS, Mahboubi P, Mahapatra NR, Mahata SK, Schork NJ, Schmid-Schoenbein GW, O'Connor DT. Common genetic mechanisms of blood pressure elevation in two independent rodent models of human essential hypertension. Am J Hypertens 18: 633-652, 2005.
7. Gonzalez-Yanes C, Sanchez-Margalet V. Pancreastatin modulates insulin signaling in rat adipocytes: mechanisms of cross-talk. Diabetes 49: 1288-1294, 2000.
8. Groop L, Orho-Melander M. The dysmetabolic syndrome. J Intern Med 250: 105-120, 2001.
9. Hsiao A, Ideker T, Olefsky JM, Subramaniam S. VAMPIRE microarray suite: a web-based platform for the interpretation of gene expression data. Nucleic Acids Res 33: W627-W632, 2005.
10. Huang DW, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc 4: 44-57, 2009.
11. Kim T, Gondre-Lewis MC, Arnaoutova I, Loh YP. Dense-core secretory granule biogenesis. Physiology 21: 124-133, 2006.
12. Kim T, Tao-Cheng JH, Eiden LE, Loh YP. Chromogranin A, an "on/off" switch controlling dense-core secretory granule biogenesis. Cell 106: 499-509, 2001.
13. Mahapatra NR, O'Connor DT, Vaingankar SM, Hikim AP, Mahata M, Ray S, Staite E, Wu H, Gu Y, Dalton N, Kennedy BP, Ziegler MG, Ross J, Mahata SK. Hypertension from targeted ablation of chromogranin A can be rescued by the human ortholog. J Clin Invest 115: 1942-1952, 2005.
14. Mahata SK, Mahata M, Wen G, Wong WB, Mahapatra NR, Hamilton BA, O'Connor DT. The catecholamine release-inhibitory "catestatin" fragment of chromogranin A: naturally occurring human variants with different potencies for multiple chromaffin cell nicotinic cholinergic responses. Mol Pharmacol 66: 1180-1191, 2004.
15. McBride P. Triglycerides and risk for coronary artery disease. Curr Atheroscler Rep 10: 386-390, 2008.
16. O'Connor DT, Cadman PE, Smiley C, Salem RM, Rao F, Smith J, Funk SD, Mahata SK, Mahata M, Wen G, Taupenot L, Gonzalez-Yanes C, Harper KL, Henry RR, Sanchez-Margalet V. Pancreastatin: multiple actions on human intermediary metabolism in vivo, variation in disease, and naturally occurring functional genetic polymorphism. J Clin Endocrinol Metab 90: 5414-5425, 2005.
17. O'Connor DT, Kailasam MT, Kennedy BP, Ziegler MG, Yanaihara N, Parmer RJ. Early decline in the catecholamine release-inhibitory peptide catestatin in humans at genetic risk of hypertension. J Hypertens 20: 1335-1345, 2002.
18. 352-372): naturally occurring amino acid variant Gly364Ser causes profound changes in human autonomic activity and alters risk for hypertension. Circulation 115: 2271-2281, 2007.
19. Salem RM, Cadman PE, Chen Y, Rao F, Wen G, Hamilton BA, Rana BK, Smith DW, Stridsberg M, Ward HJ, Mahata M, Mahata SK, Bowden DW, Hicks PJ, Freedman BI, Schork NJ, O'Connor DT. Chromogranin A polymorphisms are associated with hypertensive renal disease. J Am Soc Nephrol 19: 600-614, 2008.
20. Salomonis N, Hanspers K, Zambon AC, Vranizan K, Lawlor SC, Dahlquist KD, Doniger SW, Stuart J, Conklin BR, Pico AR. GenMAPP 2: new features and resources for pathway analysis. BMC Bioinformatics 8: 217, 2007.
21. Sanchez-Margalet V, Calvo JR, Goberna R. Glucogenolytic and hyperglycemic effect of 33-49 C-terminal fragment of pancreastatin in the rat in vivo. Horm Metab Res 24: 455-457, 1992.
22. Sanchez-Margalet V, Calvo JR, Lucas M, Goberna R. Pancreastatin and its 33-49 C-terminal fragment inhibit glucagon-stimulated insulin in vivo. Gen Pharmacol 23: 637-638, 1992.
23. Sanchez-Margalet V, Gonzalez-Yanes C, Santos-Alvarez J, Najib S. Pancreastatin. Biological effects and mechanisms of action. Adv Exp Med Biol 482: 247-262, 2000.
24. Sanchez-Margalet V, Lucas M, Goberna R. Pancreastatin: further evidence for its consideration as a regulatory peptide. J Mol Endocrinol 16: 1-8, 1996.
25. Sanchez-Margalet V, Valle M, Lobon JA, Maldonado A, Escobar-Jimenez F, Olivan J, Perez-Cano R, Goberna R. Increased plasma pancreastatin-like immunoreactivity levels in non-obese patients with essential hypertension. J Hypertens 13: 251-258, 1995.
26. Takiyyuddin MA, Parmer RJ, Kailasam MT, Cervenka JH, Kennedy B, Ziegler MG, Lin MC, Li J, Grim CE, Wright FA, O'Connor DT. Chromogranin A in human hypertension. Influence of heredity. Hypertension 26: 213-220, 1995.
27. Taupenot L, Harper KL, O'Connor DT. The chromogranin-secretogranin family. N Engl J Med 348: 1134-1149, 2003.
28. Vadigepalli R, Chakravarthula P, Zak DE, Schwaber JS, Gonye GE. PAINT: a promoter analysis and interaction network generation tool for gene regulatory network identification. OMICS 7: 235-252, 2003.
29. Yokoyama H, Emoto M, Fujiwara S, Motoyama K, Morioka T, Komatsu M, Tahara H, Shoji T, Okuno Y, Nishizawa Y. Quantitative insulin sensitivity check index and the reciprocal index of homeostasis model assessment in normal range weight and moderately obese type 2 diabetic patients. Diabetes Care 26: 2426-2432, 2003.
30. Zhang K, Rao F, Wen G, Salem RM, Vaingankar S, Mahata M, Mahapatra NR, Lillie EO, Cadman PE, Friese RS, Hamilton BA, Hook VY, Mahata SK, Taupenot L, O'Connor DT. Catecholamine storage vesicles and the metabolic syndrome: the role of the chromogranin A fragment pancreastatin. Diabetes Obes Metab 8: 621-633, 2006.